 CORAL GABLES, Fla., Sept. 30, 2021 GLOBE NEWSWIRE -- Catalyst Pharmaceuticals, Inc. Catalyst Nasdaq: CPRX, a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported that it has received a positive decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the U.S. Food and Drug Administrations FDA approval of another amifampridine product, Ruzurgi, for pediatric patients with Lambert-Eaton myasthenic syndrome LEMS despite existing Orphan Drug exclusivity for Catalysts Firdapse amifampridine Tablets 10 mg. 